68ga-rm2
Small moleculeexperimentalImaging agent
Clinical trial activity
18 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
14
Phase 3
2
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02440308)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- (68)ga-dota-4-amino-1-carboxymethylpiperidine-d-phe-gln-trp-ala-val-gly-his-sta-leu-nh2
- 68ga-dota-bombesin
- 68ga rm2
- 68ga rm2
- 68ga-rm2
- 68ga-rm2
- 68ga-rm2
- bay 86-7548
- bay 86-7548
- bay86-7548
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06247995 | Phase 1/Phase 2 (Phase 2) | Aug 14, 2024 | Novartis |
| NCT06379217 | Phase 1 | Jul 29, 2024 | Novartis |
| NCT05739942 | Phase 1 | Apr 1, 2024 | Novartis |
| NCT05870579 | Phase 1 | Nov 13, 2023 | Novartis |
| NCT05889728 | Phase 2 | Feb 20, 2023 | Novartis, University of New South Wales |
| NCT06484361 | Phase 2 | Sep 9, 2020 | Vita-Salute University of Milano. Italy |
| NCT04264208 | Phase 2 | Jul 31, 2020 | Stanford University |
| NCT05806853 | Phase 2 | Jun 3, 2020 | Vita-Salute University of Milano. Italy |
| NCT03872778 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Advanced Accelerator Applications |
| NCT03949517 | Phase 1/Phase 2 (Phase 2) | Apr 9, 2019 | General Electric, Stanford University |
| NCT03809078 | Phase 2 | Jan 14, 2019 | General Electric, Stanford University |
| NCT03731026 | Phase 3 | Nov 30, 2018 | Lightpoint Medical Limited |
| NCT03606837 | Phase 2 | Sep 1, 2018 | University of Bordeaux |
| NCT03724253 | Phase 2 | Jul 6, 2018 | Advanced Accelerator Applications |
| NCT02624518 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2015 | National Cancer Institute (NCI), Stanford University |
| NCT02559115 | Phase 2 | Sep 1, 2015 | Cornell University |
| NCT02483884 | Phase 1/Phase 2 (Phase 2) | May 1, 2015 | Piramal |
| NCT02440308 | Phase 2 | Apr 1, 2015 | National Cancer Institute (NCI), Stanford University |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 4 | 2 | 2023 |
| Stanford University | Academic/Hospital | 5 | 5 | 2 | 2015 |
| Advanced Accelerator Applications | For profit | 2 | 2 | 1 | 2018 |
| General Electric | For profit | 2 | 0 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2015 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Lightpoint Medical Limited | For profit | 1 | 1 | 1 | 2018 |
| Piramal | For profit | 1 | 1 | 1 | 2015 |
| University of Bordeaux | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2023 |
11 organizations
Page 1 / 1